Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Effect of probiotics on C-reactive protein levels in preterm infants: Secondary analysis of a randomized controlled
S Agrawal1,2,3, S Rao1,2,3, E A Nathan4,5
1Department of Neonatal Paediatrics, KEM Hospital, Perth, WA, Australia.
Insights
Bifidobacterium breve m-16v did not significantly alter C-reactive protein (CRP) levels in preterm infants. This study found no evidence that probiotics reduce inflammation markers in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Microbiology
- Immunology
Background:
- Excessive inflammation in preterm infants is linked to poor outcomes.
- C-reactive protein (CRP) is a key indicator of inflammation and infection.
- Probiotics are known for their anti-inflammatory potential, but their effect on CRP in preterm infants remains under-researched.
Purpose of the Study:
- To investigate the impact of Bifidobacterium breve (B. breve) m-16v supplementation on CRP levels in preterm infants.
- To analyze CRP data from a randomized controlled trial (RCT) involving preterm infants.
Main Methods:
- Analysis of data from 159 preterm infants (gestational age <33 weeks) participating in an RCT.
- Defined normal CRP levels as <15 mg/L in the first week and ≤10 mg/L thereafter.
- Employed mixed logistic regression to assess the effect of probiotics on CRP.
Main Results:
- A total of 1579 CRP measurements were analyzed (851 in the probiotic group, 728 in the placebo group).
- No significant difference was observed in the proportion of infants with elevated CRP over time or across all time points between the probiotic and placebo groups (adjusted OR: 1.62, 95% CI: 0.91-2.88).
Conclusions:
- Bifidobacterium breve m-16v supplementation did not lead to a decrease in CRP levels in preterm infants born before 33 weeks gestation.
- The findings suggest that this specific probiotic strain may not be effective in modulating inflammatory markers like CRP in this population.
Background:
Excessive inflammation is associated with adverse outcomes in preterm infants. C- reactive protein (CRP) is a marker of inflammation/infection. Probiotics have anti-inflammatory properties. Randomized controlled trials (RCTs) in preterm infants have not reported effect of probiotics on CRP.
Aim:
To evaluate effect of probiotics on CRP in preterm infants who had participated in a RCT of Bifidobacterium breve (B. breve) m-16v.
Methods:
Data on all infants (GA <33 weeks, n = 159) enrolled in the RCT was analyzed. For study purpose, CRP <15 mg/L and ≤10 mg/L was considered normal for the first week, and thereafter respectively. Mixed logistic regression modelling was used to assess probiotic effect on CRP levels.
Results:
There were 1579 CRP measurements (Probiotic: 851 vs. Placebo: 728). Baseline characteristics and number [Median (IQR)] of CRP estimations per infant [l0 (5, 20) vs. 10 (6, 17), p = 0.861] were comparable between probiotic vs. placebo group. There was no significant difference in the proportion of infants with high CRP over time (treatment by weekly time points interaction, p = 0.187), and across all time points between probiotic and placebo group (adjusted OR: 1.62, 95% CI: 0.91-2.88, p = 0.102)CONCLUSION:B. breve m-16v did not decrease CRP levels in preterm infants born <33 weeks.
Related Concept Videos
Secondary Active Transport
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Secondary Healthcare System

